RxDoctor Payments Data

Michelle Boothe, PA

Physician Assistant · London, KYNPI 1457660102

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 75 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$476
  • Novo Nordisk$319
  • Lilly USA, LLC$146
  • AbbVie$127
  • Merck$118
  • GSK$61
  • plus $231 from 9 others

What the payments were for

  • Food & beverage$1,479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,479 in reported general payments places this provider in the 70th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,532
Medicare patients
24
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$138,557
JardianceEmpagliflozin107$88,714
TrulicityDulaglutide36$51,607
MounjaroTirzepatide44$46,748
EliquisApixaban32$32,107
RybelsusSemaglutide17$22,104
XareltoRivaroxaban33$19,283
Nurtec OdtRimegepant Sulfate14$17,410
Tresiba Flextouch U-200Insulin Degludec13$14,746
FarxigaDapagliflozin Propanediol12$12,605
UbrelvyUbrogepant13$11,983
Combivent RespimatIpratropium/Albuterol Sulfate14$11,974
TradjentaLinagliptin12$10,384
Breo ElliptaFluticasone/Vilanterol16$8,985
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$7,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$319$160,661131 claims
Lilly USA, LLCTrulicity, Mounjaro$146$98,35580 claims
PfizerEliquis, Nurtec Odt$29$49,51746 claims
Johnson & JohnsonXarelto$15$19,28333 claims
AbbVieUbrelvy, Synthroid$127$16,53683 claims
GSKBreo Ellipta, Trelegy Ellipta$61$15,54428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in London

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →